CXCL10 overexpression is associated with accelerated development of T1D,6 and blocking the interaction of CXCL10 with its cognate receptor CXCR3 using neutralizing antibodies reduces the incidence of T1D in mice.7 Here, CXCR3 is linked to type 1 diabetes mellitus.